Tareen Dermatology, P.A., Dr. Mohiba Tareen, and Basir Tareen, CEO, agreed to pay the United States $1.63 million to resolve allegations that they violated the False Claims Act, including claims brought under the qui tam, or whistleblower provisions, by submitting false claims to Medicare and other government payors for dermatology services and treatment. The settlement resolves allegations that the defendants caused false claims to be submitted to Medicare and VA-administered programs in connection with Mohs surgeries, services billed as though performed under the supervision of Dr. Tareen on days she was not physically present in the clinic, office visits for which the defendants inappropriately waived beneficiary co-pays, and the use of certain skin grafts in circumstances in which their usage was not justified as billed. Read a Department of Justice press release.